Kayak Therapeutics Announces IND Clearance for KT-300
The company said KT-300 is an oral small-molecule TRIM7 inhibitor designed to target RAS-driven cancers.
The company said KT-300 is an oral small-molecule TRIM7 inhibitor designed to target RAS-driven cancers.